ReviewJournal of clinical medicine2026
Artificial Intelligence in Asthma and COPD: Current Status and Future Potential.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in artificial intelligence (AI) is rapidly growing. In healthcare, especially through machine learning and deep learning, AI is emerging as a promising tool to support the diagnosis, management, and prevention of lung diseases and to advance personalized care, although it requires large, well-structured datasets. Clinicians must learn how to integrate AI into routine practice for conditions such as asthma and chronic obstructive pulmonary disease (COPD), while ensuring patient safety and building trust in these tools. Chronic respiratory diseases are major global causes of morbidity and mortality and place a substantial burden on healthcare systems; among them, asthma and COPD are chronic disorders characterized by airway obstruction and inflammation. This review highlights the rapid advancement of AI, and it aims to explore the literature's evidence of its applicability in controlling chronic respiratory disorders, particularly in asthma and COPD. We conducted a narrative literature review by searching ScienceDirect, PubMed, and Google Scholar for English-language studies on artificial intelligence applications in asthma and COPD and by screening the references of relevant articles. The reviewed literature suggests that AI-based approaches are being applied across the asthma-COPD spectrum to support diagnosis and phenotyping, improve risk stratification and prediction of clinically relevant outcomes, and enable more continuous monitoring using heterogeneous data sources (e.g., clinical records, imaging, and digital health data). AI-based tools are poised to support clinicians in asthma and COPD across diagnosis, phenotyping, and monitoring; however, their safe implementation in routine care will require robust validation, transparency, and governance to ensure reliability and patient safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.